Compare Abeona Therapeutics Inc (ABEO) vs Booz Allen Hamilton Holding Corporation (BAH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Booz Allen Hamilton Holding Corporation — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Booz Allen Hamilton Holding Corporation trades at $63 (market cap $7.59B). The key difference: Booz Allen Hamilton Holding Corporation is far larger — about 20.3× Abeona Therapeutics Inc's market cap, and Booz Allen Hamilton Holding Corporation pays a 3.73% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | BAH | |
|---|---|---|
Market Cap | $373.32M | $7.59B |
Sector | Health | Industrials |
52-Week High | $7.23 | $115.95 |
52-Week Low | $4.17 | $59.71 |
Enterprise Value | $228.22M | $10.99B |
Dividend Yield | — | 3.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Booz Allen Hamilton (BAH) trades at $63.31, up 1.38% with mixed technical signals showing bearish moving averages but neutral oscillators. The company demonstrates strong fundamentals with revenue growth to $12.0B in 2025 and impressive profitability metrics including 80.17% ROE. Recent developments include strategic AI partnerships with OpenAI and acquisitions to strengthen defense technology capabilities, though the stock faces near-term pressure from civil business weakness.
BAH presents a compelling value opportunity with attractive valuation multiples (P/E 9.03, P/S 0.68) and analyst consensus target of $87.25 representing 38% upside. However, investors face risks from FY27 transition expectations, civil segment pressures, and technical resistance near $64-65 levels. The company's government-focused model provides stability amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp is a provider of management consulting services to the U.S. government. Other services offered include technology, such as cloud computing and cybersecurity consulting, and engineering consulting. The consulting services are focused on defense, intelligence, and civil markets. In addition to the U.S. government, Booz Allen Hamilton provides its management and technology consulting services to large corporations, institutions, and nonprofit organizations. The company assists clients in long-term engagements around the globe.
Read more on BAH →
